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Introduction
Angiotensin II (Ang II) is known to induce cardiac growth and modulate myocardial contractility. It has been reported that elevated levels of endogenous Ang II contribute to the development of cardiac hypertrophy in hypertensives. However, the long-term functional effects of cardiac exposure to Ang II in normotensives is unclear.
A recently developed transgenic mouse (TG1306/1R), in which cardiac-specific overproduction of Ang II produces primary hypertrophy, provides a new experimental model for investigation of this phenotype. The aim of the present study was to use this model to investigate whether there is a functional deficit in primary hypertrophy that may predispose to cardiac failure and sudden death. We hypothesised that primary cardiac hypertrophy is associated with mechanical dysfunction in the basal state.
Methods
Normotensive heterozygous TG1306/1R mice harbouring multiple copies of a cardiac-specific rat angiotensinogen gene 1 were studied at age 30-40 weeks and compared with age-matched wild-type littermates. Left ventricular function was measured ex vivo in bicarbonate buffer-perfused, Langendorffmounted hearts (at a perfusion pressure of 80 mmHg, 37°C) using a fluid-filled PVC balloon interfaced to a pressure transducer and digital data acquisition system.
Results
There was no difference in the mean (+SEM) intrinsic heart rate of TG1306/1R and wild-type control mice (357.4+11.8 vs. 367.5+20.9 bpm, n=9 & 7) . Under standardised end-diastolic pressure conditions, TG1306/1R hearts exhibited a significant reduction in peak developed pressure (132.2+9.4 vs. 161.5+3.1 mmHg, n=9 & 7, p<0.05) and maximum rate of pressure development (3566.7+323.7 vs. 4486.3+109.4 mmHg, n=9 & 7, p<0.05). TG1306/1R mice show a significant correlation between incidence of arrhythmia and increasing heart size (Spearman's correlation coefficient 0.61).
Conclusion
These data demonstrate that chronic in vivo exposure to elevated levels of intra-cardiac Ang II is associated with significant contractile abnormalities evident in the ex vivo intact heart. Our findings suggest that endogenous overproduction of cardiac Ang II, independent of changes in blood pressure, is sufficient to induce ventricular remodelling that culminates in impaired cardiac function which may precede failure.
Introduction
Cardiac enlargement (hypertrophy) is a remodelling process that involves not only a rearrangement of the structural features of the heart muscle, but also alterations in the contractile, electrical and signalling processes in the myocardium. [2] [3] [4] Cardiac hypertrophy is a significant cardiovascular risk factor. The findings of the Framingham Heart Study provide evidence that, after age, left ventricular mass is the next most important single risk factor associated with cardiovascular morbidity and mortality. 5 Whilst it is now accepted that circulating angiotensin II (Ang II) has a role in influencing cardiac growth and development, 6,7 more recent evidence indicates that the heart is capable of de novo synthesis of Ang II that is involved in growth regulation. The discovery of renin and angiotensinogen mRNA in cardiac tissue, 8 and the production of Ang II by isolated perfused hearts, 9 are all indications that a local renin-angiotensin system (RAS) operates in the heart. 8 It is thus possible that in the absence of a workload trigger, increased activity of the intracardiac RAS stimulates primary hypertrophy.
Most animal models available to study the hypertrophic effects of increased endogenous cardiac levels of Ang II are hypertensive models. This makes it difficult to determine whether Ang II can exert a growth effect entirely in the absence of increased workload, and if the elevated blood pressure and subsequent wall stress are essential co-signals to trigger Ang II release. 10 To resolve this question, Mazzolai et al. 1 developed a normotensive transgenic mouse model of cardiac hypertrophy, in which angiotensinogen expression was augmented specifically in the heart.
The transgenic mouse (TG1306/1R) was created by the insertion of multiple copies of the rat angiotensinogen transgene coupled to the cardiac specific mouse α-MHC gene promoter into the mouse genome. Hypertrophy (in the absence of increased fibrosis) is evident in the TG1306/1R as early as eight weeks. 1 The goal of this study was to assess ex vivo performance of hearts from the TG1306/1R mouse to evaluate the functional effects of chronic exposure to elevated levels of intra-cardiac Ang II in primary hypertrophy. 
Materials and methods

Cannulation and perfusion
Male mice were anaesthetised using pentobarbitone sodium ('Nembutal', 70 mg/kg, intraperitoneally). Hearts were excised and wet weight determined by tare for subsequent calculation of cardiac weight index (CWI). Hearts were perfused at a constant pressure of 80 mmHg in Langendorff mode and allowed to spontaneously beat at 37°C. A small plastic drain was inserted into the left ventricle to prevent intraventricular pressure development throughout the experimental protocol. After cannulation, hearts were immersed in a water-jacketed organ bath, maintained at 37°C. Hearts were perfused with a modified Krebs-Henseleit buffer, which consisted of: NaCl 119 mM, glucose 5 mM, NaHCO 3 22 mM, KCl 4 mM, MgCl 1.2 mM, KH 2 PO 4 1.2 mM, EDTA 0.5 mM, CaCl 2 2.5 mM, insulin 100 µU/ml. The perfusate was then equilibrated with carbogen (95%O 2 , 5%CO 2 ) at 37°C and filtered before use with a 0.45 µm Millipore filter.
Ventricular pressure measurement
For assessment of isovolumic function, a small balloon was inserted into the left ventricle via the mitral valve. Fluid-filled balloons (~5 mm in length when deflated) were constructed using flexible plastic wrap. 11 Balloons were connected to a pressure transducer (MLT 844, ADInstruments, Castle Hill, Australia) using fluid-filled polyethylene tubing. After the balloon was in position in the left ventricle, the fluid volume was then adjusted with a calibrated Hamilton 100 µl plunger syringe.The volume was adjusted in situ until an end-diastolic pressure of approximately 5 mmHg was measured. Care was taken to ensure that the balloon, transducer line, and pressure transducer were free from any bubbles to prevent a damped signal. Phasic left-ventricular pressure, detected by the balloon interfaced-transducer was recorded on a MacLab data acquisition system, (Chart 3.5.1 Analog Digital Instruments, Castle Hill, Australia), at a sampling rate of 1,000/s. Cardiovascular parameters were measured on-line from the balloon pressure signal, including heart rate (HR, bpm), systolic pressure (SP, mmHg), diastolic pressure (DP, mmHg), developed pressure (DevP = SP-DP), the rate of pressure development (+dP/dt, mmHg/s), rate of pressure decline (-dP/dt, mmHg/s) and time to relaxation (TTR, ms). The coronary flow was monitored by timed collection of the coronary effluent (TG1306/1R 4.1+0.3 ml/min; wild-type 4.4+0.9 ml/min) and no differences were found in flow rate or flow normalised for heart mass between the two groups.A temperature probe (Physitemp, BAT-12, NJ, USA) was inserted into the infusion port at the top of the cannula to continuously monitor the perfusate temperature (~37°C) as it entered the heart. The heart submersion bath temperature was monitored every five minutes.
Experimental protocol
Following cannulation, establishment of aerobic perfusion, and insertion of the intraventricular balloon, hearts were monitored continuously and allowed to stabilise for fifteen minutes. After stabilisation, to compare basal performance of transgenic and wild-type control mice, data was acquired (minimum 50 cycles) to evaluate heart pressure and rate parameters.
In conjunction with pressure and rate parameters, evidence for the occurrence of arrhythmias under basal conditions was sought. Where evident, arrhythmias were classified to one of the following three groups. 12 1. Ventricular premature beat (VPB): a discrete new systolic 'wave' that was premature preventing completion of relaxation. 2. Ventricular tachycardia (VT): four or more consecutive ventricular premature beats. 3. Ventricular fibrillation (VF): a barely discernible pressure 'wave' of less than 5 mmHg which was distinct from asystole. Arrhythmia occurrence was counted manually from the pressure trace. Hearts were excluded from pressure data analysis if the extent of arrhythmia precluded the determination of an average stable performance over a 50-cycle period. Using exclusion criteria previously adopted for the mouse Langendorff model, 11 hearts from the wild-type control group were excluded if they were bradycardic (heart rate <250 bpm).All hearts were included in the analysis of arrhythmia.
Statistical analysis
Data are expressed as mean + standard error of the mean (SEM). Perfusion parameters were analysed using Students unpaired t-test. Data was considered significant at p<0.05. Occurrence of arrhythmia was analysed using Spearman's nonparametric correlation coefficient. A value of p<0.05 was considered significant. All statistical calculations were performed using the SPSS statistical analysis package (V 11.0). 
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Results
A summary of the mouse characteristics are shown in Table 1 .There were no significant body weight differences between the two experimental groups. Mice were closely matched for age, and at the mean age of 31-33 weeks were considered mature adults.TG1306/1R hearts were about 15% larger than the littermate wild-type controls, this difference being reflected in a significant difference in the CWI between the two groups (10.4+0.5 vs. 8.9+0.6 mg/g). This degree of hypertrophy is similar to that previously reported for these transgenic mice, measured at an earlier developmental stage. 1 Basal cardiac function measurements, averaged over 50 cycles after 15 minutes' stabilisation under normoxic conditions, are presented in Figures 1-3 . Under the basal conditions established, the TG1306/1R hearts had significantly reduced contractile function. SP and DevP were lower by approximately 18%. DP was set equally for both groups at the commencement of perfusion and remained similar throughout the stabilisation period for both groups.
The value of +dP/dt was significantly reduced in TG1306/1R mice compared with wild-type control mice (3566.7+322.7 vs. 4486.3+109.4 mmHg/s). In addition, -dP/dt tended to be lower by approximately 15% (not significant) in the transgenic group, suggestive of a lesser degree of dysfunction during relaxation (Figure 1 ). Consistent with this data is the observation that TTR (Figure 2) is slightly, but not significantly, prolonged in the transgenic mice.These reductions in contractile function of the TG1306/1R were not due to differences in intrinsic heart rate (357+12 vs. 368+21 bpm, Figure 2) .
To evaluate the extent to which performance is influenced by heart size per se, an investigation of the relationship between SP and CWI for both animal groups was undertaken. Figure 3 illustrates the regression relationship between SP and CWI for wild-type and TG1306/1R mice. In both cases, the gradient of the fitted regression line was negative, but no significant relationship between SP and CWI PAPER In addition to the mechanical dysfunction seen in the transgenics, there is indirect evidence that cardiac hypertrophy is associated with electrical instability in the transgenic mice. Figure 4 shows that there is a significant correlation (Spearman's coefficient = 0.61) between the degree of cardiac hypertrophy and the incidence of arrhythmia, predominantly in the form of VPBs and VT, indicative of incomplete relaxation.
Discussion
This study demonstrates that, under basal ex vivo conditions, there are clear deficits in the contractile performance of hypertrophic hearts from the TG1306/1R, as demonstrated by decreased peak systolic pressure, decreased developed pressure and reduced rate of pressure development, relative to wild-type controls. The intrinsic ex vivo heart rates of the TG1306/1R and wild-type groups were not different, a finding consistent with previous reports that the in vivo heart rates of these animals are similar. 1 In the transgenic mice, a higher incidence of arrhythmia was observed under basal conditions. In particular, VPBs and bursts of tachyarrhythmia were evident. Collectively, these contractile and rhythm disturbances are indicative of both systolic and diastolic dysfunction in the TG1306/1R. Interestingly, although the degree of hypertrophy in the TG1306/1R is relatively modest (17% increase in CWI), the extent of the associated mechanical and electrical disturbance is quite marked.
Disturbances in cardiomyocyte calcium (Ca 2+ ) homeostasis have been previously associated with the occurrence of cardiac hypertrophy, albeit in situations in which the hypertrophy development is secondary to altered haemodynamic loading or endocrinological status. 13 The most frequently observed alteration is a down-regulation of the expression and activity of the sarcoplasmic reticulum (SR) Ca 2+ pump (SERCa2) with, in some instances, an increase in the expression of the sarcolemmal Na + -Ca 2+ exchanger. 14, 15 The functional deficits we describe in relation to this transgenic model of primary hypertrophy, would seem consistent with similar alterations in cardiomyocyte Ca 2+ handling. In particular, the reduced systolic pressure and developed pressure could indicate diminished Ca 2+ stores in the SR, reflecting impaired SR Ca 2+ uptake via SERCa2. Some impact on delayed relaxation would also be expected, a trend which was observed in the present study (reduced -dP/dt and increased TTR), but which did not attain significance in this data set.
An increased reliance on the Na + -Ca 2+ exchanger to mediate Ca 2+ efflux during the relaxation phase may underlie the arrhythmogenic propensity observed in the transgenics. The generation of depolarising inward current, as a consequence of Ca 2+ exit via the exchanger in the diastolic period, may trigger extrasystolic premature beats and initiate tachyarrhythmic activity.
Systolic dysfunction has also been related to impaired Ca 2+ release in hypertrophic hearts derived from various models, and the reduced rate of pressure development observed in the TG1306/1R may reflect altered SR Ca 2+ release characteristics. Reduced expression of the ryanodine receptor, or of the more recently discovered SR Ca 2+ regulatory protein 'junctin', 16 may be involved. Additional experiments to assess cardiomyocyte Ca 2+ dynamics and transporter expression levels are required to investigate these possibilities. Earlier investigation of contractile protein types in this model suggest that some alterations in contraction kinetics may also be attributable to increased expression of so-called foetal isoforms. 17 Changes in the extracellular matrix composition could also contribute to the basal contractile dysfunction seen in the TG1306/1R in this study. Although previous investigations have shown that this model is not associated with a gross increase in fibrosis, qualitative changes in the matrix composition may occur. Changes in the type of collagen, in particular an increased expression of collagen I at the expense of collagen III, may inhibit the adhesion of myocytes to the collagen fibres reducing stress transmission in the myocardium impacting on force development. 4, 18 Finally, it is possible that the performance of the TG1306/1R heart is compromised by metabolic constraints. Often associated with the hypertrophic foetal re-capitulation is the switch from oxidative phosphorylation to glycolysis. 19 In normal hearts, oxidative phosphorylation is the predominant pathway utilised to produce ATP. 20 However, it is not uncommon for the glycolytic pathway to be the main mechanism for energy production in secondary hypertrophy -a metabolic response triggered by reduced oxygen supply. 21 Although, in this model of primary hypertrophy, the absence of fibrotic growth implies that there is no additional barrier to oxygen diffusion as is evident in other conditions of secondary hypertrophy, it is possible that the increase in tissue mass represents a partially unmet demand for oxygen delivery. If there is a relatively increased reliance on glycolytic metabolism in the TG1306/1R heart, this may be indicative of an adaptive mechanism to deal with periods of metabolic challenge, such as those associated with transient ischaemic events. The bicarbonate perfusion buffer used in the present study offers a minimally sufficient substrate, and may selectively limit the capacity of the transgenic hearts to perform contractile work. A more complete evaluation of substrate dependence would yield insight into the question of whether the transgenic has a greater preference for glucose or fatty acids as energy sources, and whether an optimal combination can be achieved to offset the performance deficits observed.
In summary, the present study has demonstrated that the development of primary cardiac hypertrophy in response to cardiac-specific Ang II overexpression is associated with significant disturbance of basal cardiac contractility and rhythm. These findings, based on ex vivo intact heart experiments, indicate that hypertrophy per se, even in the absence of altered systemic loading and/or endocrinological derangement, is associated with intrinsic cardiac dysfunction. The role of metabolic, excitation contraction coupling and structural factors in this performance deficit remain to be explored. 
